What Happened?
San Diego, CA-based aTyr Pharma Appointed Kelly Blackburn as Chief Executive Officer
About the Company
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases.
About the Person
Kelly Blackburn is Chief Executive Officer at aTyr Pharma. Previously, Kelly held various senior HR leadership roles in the industry.
Info Source
News
Short Profile